BURLINGTON, N.C., Feb. 11, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide availability of the Elecsys® ...
Labcorp’s testing capabilities are getting a little broader with the $237.5 million acquisition of certain laboratory assets from BioReference Health, a subsidiary of Opko Health. The BioReference ...
Labcorp’s (NYSE:LH) assay has been cleared by the U.S. drug regulator for use with Pfizer's (NYSE:PFE) newly approved gene therapy to treat patients with hemophilia B. The U.S. Food and Drug ...
The FDA has bestowed a green light to a companion diagnostic for Pfizer’s recently approved hemophilia B gene therapy—because, at a cost of $3.5 million per dose, you want to make sure it will work.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results